Hikma Pharmaceutical | HIK - Equity Capital And Reserves


Hikma Pharmaceutical reported $2.59B in Equity Capital and Reserves for its fiscal semester ending in December of 2025.





Equity Capital And Reserves Change Date
Almirall EUR 1.53B 43.26M Jun/2026
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Autolus Therapeutics Ltd USD 74.84M 33.99M Jun/2026
Bayer EUR 29.71B 863M Jun/2026
Fresenius EUR 19.7B 766M Jun/2026
Genmab DKK 5.96B 275M Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Orion EUR 1.27B 146.5M Jun/2026
Recordati EUR 2.13B 70.34M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025